| Tumor mutational burden is a potential predictive biomarker for response to immune checkpoint inhibitors in patients with advanced biliary tract cancer SS Liddell, S Chakrabarti, GA Wintheiser, TJ Zemla, Q Shi, SH Tella, Z Jin, ... JCO Precision Oncology 6, e2200003, 2022 | 6 | 2022 |
| Impact of perioperative chemotherapy on survival in patients with cholangiocarcinoma undergoing curative resection H Hassan, S Chakrabarti, T Zemla, J Yin, V Wookey, K Prasai, ... European Journal of Surgical Oncology 49 (11), 106994, 2023 | 2 | 2023 |
| P-181 Outcomes of neoadjuvant and/or adjuvant treatment vs surgical resection alone for patients with cholangiocarcinoma: An inverse probability of treatment weighting with … H Hassan, W Vanessa, T Zemla, J Yin, K Prasai, A Abdellatief, R Katta, ... Annals of Oncology 33, S314, 2022 | | 2022 |
| EVALUATION OF FACTORS ASSOCIATED WITH OUTCOMES OF HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH LIVER RESECTION: A REAL WORLD DATA ANALYSIS MM Ali, N Rodriguez-Payan, JJ Larson, J Yin, HM Hassan, ... HEPATOLOGY 74, 640A-641A, 2021 | | 2021 |
